### Analysis

**Short-term implications for Johnson & Johnson:**

1. **Financial Performance:**
   - **Q3 Sales:** $17.1 billion, up 6.5% compared to Q3 2011.
   - **Net Earnings:** $3 billion, down from $3.2 billion in Q3 2011.
   - **EPS:** $1.05, down from $1.15 in Q3 2011.

2. **Operational Growth:**
   - **Pharmaceuticals:** 11.3% growth.
   - **MD&D:** 16.1% growth.
   - **Consumer:** 1% growth.

3. **Guidance:**
   - **Sales:** $68.6 billion to $69.3 billion for 2012.
   - **EPS:** $5.27 to $5.32 for 2012.

4. **Pipeline and Product Launches:**
   - **Pharmaceuticals:** Strong growth in key therapeutic areas like immunology, oncology, and infectious diseases.
   - **MD&D:** Successful product launches in energy and orthopedics.
   - **Consumer:** Positive developments in OTC products and Digestive Health.

5. **Market Conditions:**
   - **Pharmaceuticals:** Continued growth despite patent expirations and competitive pressures.
   - **MD&D:** Challenges in Europe due to competitive pressures and lower procedure volumes.
   - **Consumer:** Positive trends in OTC products and Digestive Health.

6. **Integration and Acquisitions:**
   - **Synthes Acquisition:** Initial integration is proceeding smoothly, with no significant disruptions.

### Conclusion

**Rating: 1**

**Explanation:**
The results for Johnson & Johnson are mixed, with a decline in net earnings and EPS, but strong sales growth in key segments. The company is benefiting from strong pipeline growth and new product launches. However, there are challenges in certain markets, particularly in Europe for MD&D. The integration of Synthes is proceeding smoothly. Overall, while there are some short-term concerns, the company is well-positioned for long-term growth. The stock is likely to experience some volatility but should remain steady in the short term.